SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
Five diagnostic tools are critical to assist surgeons in choosing the most appropriate IOL for the patient and maintaining ...
GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR ...
Dec 9 (Reuters) - Swiss eyecare giant Alcon (ALCC.S), opens new tab has made a new offer for Staar Surgical (STAA.O), opens new tab worth $1.6 billion, it said on Tuesday, as it seeks to clinch a deal ...
Alcon ALC-0.55%decrease; red down pointing triangle shares in Switzerland rose after the eye-care specialist reported an acceleration in third-quarter sales growth and confirmed its annual outlook, ...
In August, Geneva, Switzerland-based eye care company Alcon agreed to buy Staar Surgical in a deal valued at $1.5 billion, but STAAR has faced opposition to the deal, including from its largest ...
†Compared to CENTURION and CONSTELLATION Vision Systems. Based on bench data. **Based on worldwide unit sales of AcrySof® IQ Vivity and Clareon Vivity IOLs, as of Q4, 2024. “As ophthalmic practices ...
GENEVA, SWITZERLAND - One might imagine that top management at Alcon, the global eyecare company with manufacturing and research facilities in Berks County, are not very happy with the U.S. tariff ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback